Legal Status and Safety

Online sellers sometimes present MOTS-c as a harmless "mitochondrial booster". Its real status is that of an unapproved, banned research substance.

Anti-Doping Rules

WADA's Prohibited List places MOTS-c in section S4.4, metabolic modulators, as an example of an activator of the enzyme AMPK, alongside AICAR. Substances in this class are banned both in and out of competition and are classed as non-specified, which can mean longer sanctions. Detection methods for doping control have been published.

Medicines Regulation

• European Union: no medicine containing MOTS-c has been authorised. Offering it to prevent or treat a disease would bring it under medicines law.
• United Kingdom: the MHRA has not licensed any MOTS-c product.
• United States: MOTS-c is not an FDA-approved drug.
• Other countries: check national rules on importing and holding research peptides.

What We Do Not Know About Safety

• No human safety data for MOTS-c itself have been published.
• Blood sugar: because it acts on insulin sensitivity, effects on glucose levels, particularly in people taking diabetes medicines, are unknown.
• Long-term signalling: MOTS-c changes gene activity in the nucleus. The consequences of doing this artificially for months or years have not been studied.
• Quality: research-grade peptides are not manufactured under pharmaceutical controls, so purity and content can vary.
• Testing: uncertainty over how to measure natural levels makes it harder to judge any exposure.

A Research Compound Only

Research-grade MOTS-c is supplied for laboratory experiments. It has no approved dose, no product information for patients and no regulatory monitoring of side effects.

In Short

MOTS-c is a promising research topic, but it is not a medicine or a supplement. Athletes risk a ban, and anyone thinking about it for health reasons should speak to a doctor.

This page is a general overview, not legal advice.